Triple GIP/GLP-1/Glucagon Receptor Agonist12 mgInvestigational

12 mg Retatrutide Dosage Calculator

Calculate the exact units for the maximum 12 mg retatrutide dose studied in clinical trials.

Retatrutide is an investigational medication currently in clinical trials. It has not been approved by the FDA for any indication.

050100

How many units is 12 mg of Retatrutide at 2 mg/mL?

Draw

600units

6.00 mL on a U-100 insulin syringe

12 mg ÷ 2 mg/mL × 100 = 600 units

This dose exceeds 50 units (0.5 mL). Volumes greater than 0.5 mL may be uncomfortable for subcutaneous injection. Consult your provider about splitting the dose into two injections.

For educational purposes only. Always follow your provider's instructions.

Quick Reference Table

All dose × concentration combinations

Dose2 mg/mL5 mg/mL10 mg/mL
1 mg502010
2 mg100*4020
4 mg200*80*40
8 mg400*160*80*
12 mg600*240*120*

Values in U-100 insulin syringe units

* Exceeds 50 units (0.5 mL) — may require splitting into two injections

There's an easier way

Tired of calculating doses?

We handle everything — the prescription, the right dose, and shipping straight to your door. No math, no hassle.

Get Started

2-min quiz · Free consultation · No commitment

About the 12 mg Dose

The 12 mg dose is the maximum dose studied in Phase 2 retatrutide clinical trials, reached at week 17 and continued through the end of the study period. This dose produced the most dramatic results in trials, with participants losing an average of 24.2% of their body weight at 48 weeks — the highest weight loss observed for any anti-obesity medication in clinical trials to date. Retatrutide remains investigational and is not yet FDA-approved.

Frequently Asked Questions

In a 10 mg/mL vial, 12 mg retatrutide equals 120 units. The calculation is (12 / 10) x 100 = 120 units. This exceeds a standard 100-unit syringe, so you would need either a larger syringe or a higher concentration vial.

The Phase 2 clinical trial reported that participants on 12 mg retatrutide lost an average of 24.2% of their body weight at 48 weeks. This is the highest average weight loss recorded for any obesity medication in clinical trials. By comparison, tirzepatide 15 mg showed approximately 22.5% and semaglutide 2.4 mg showed approximately 15% in their respective trials.

The clinical trial protocol reaches 12 mg at week 17 after escalating through 1 mg (weeks 1-4), 2 mg (weeks 5-8), 4 mg (weeks 9-12), and 8 mg (weeks 13-16). This 16-week titration period allows the body to adjust gradually to the potent triple-receptor agonist mechanism before reaching the maximum studied dose.

At their respective maximum doses, retatrutide 12 mg produced approximately 24.2% weight loss, tirzepatide 15 mg produced approximately 22.5%, and semaglutide 2.4 mg produced approximately 15% in clinical trials. Retatrutide's additional glucagon receptor activity may contribute to its superior results by increasing energy expenditure and fat oxidation on top of the appetite suppression from GIP and GLP-1 agonism.

Other Retatrutide Doses

1 mg Retatrutide2 mg Retatrutide4 mg Retatrutide8 mg Retatrutide

Related Pages

Retatrutide CalculatorRetatrutide Dosing

Ready to Get Started?

Take our 2-minute quiz to see if you qualify for GLP-1 treatment.

Start Quiz

Free consultation. No commitment.